US biotech Novavax (Nasdaq: NVAX) saw its share price jump by 14% in Tuesday morning’s trading as it became the latest company to announce that trials of its novel coronavirus vaccine have begun.
The first participants in a Phase I/II clinical trial have been enrolled in the trial of NVX CoV2373, a stable, prefusion protein made using its proprietary nanoparticle technology.
NVX CoV2373 includes Novavax’ proprietary Matrix M adjuvant to enhance immune responses and stimulate high levels of neutralizing antibodies. Preliminary immunogenicity and safety results from the Phase I portion of the trial are expected within the next two months, and if these are successful, then the Phase II portion will start.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze